Business
Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera
– NeoGenomics wins summary judgment in patent infringement lawsuit against Natera; Court rules Natera’s patents are invalid for claiming ineligible subject
About this update from Neogenomics, Inc.
[{"type":"text","content":"\n– NeoGenomics wins summary judgment in patent infringement lawsuit against Natera; Court rules Natera’s patents are invalid for claiming ineligible subject matter\n\n\n– NeoGenomics remains free to make, use, sell, and promote its RaDaR ST molecular residual disease (MRD) assay in the United States\n\n\n FORT MYERS, Fla.--(BUSINESS WIRE)--\nNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the District Court for the Middle District of North Carolina has granted NeoGenomics’ motion for summary judgment that all of Natera’s asserted patent claims are invalid for claiming ineligible subject matter. The Court stated that it will dismiss Natera’s claims against NeoGenomics with prejudice and enter declaratory judgment of invalidity of both of Natera’s asserted patents.\n\n\nThe order means that NeoGenomics remains free to broadly commercialize the RaDaR® ST assay, formerly RaDaR 1.1. NeoGenomics has launched RaDaR ST to biopharma customers and has submitted to the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) for clinical reimbursement coverage for the RaDaR ST assay.\n\n\n“We are pleased with the Court’s decision to invalidate Natera’s asserted patents. NeoGenomics is committed to providing cancer patients the most comprehensive array of diagnostic testing options to enable the highest quality of personalized care, which includes providing options for their MRD testing,” said Tony Zook, CEO of NeoGenomics. “We will continue to vigorously protect and defend our intellectual property to fuel the next wave of innovation and serve our patients.”\n\n\nAbout NeoGenomics\n\n\nNeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the U.S. and a CAP-accredited full-service sample-proce...